Dallas, TX -- (SBWire) -- 06/07/2010 -- ReportsandReports Announce it Will Carry the Pharmaceutical Research and Development (R&D) - Increasing Efficiency through Information Technology and Externalization Market Research Report in its Store.
Browse the complete Report on: http://www.reportsandreports.com/market-reports/pharmaceutical-research-and-development-rd-increasing-effici/
GBI Research’s pharma report, “Pharmaceutical Research and Development (R&D) - Increasing Efficency Through Information Technology and Externalization” provides key data, information and analysis on major pharmaceutical R&D practices at the global level in order to improve its efficiency and effectiveness. This pharmaceutical and healthcare report provides comprehensive insight into the major challenges in the current pharmaceutical R&D landscape. It analyzes key measures and practices (mergers and acquisitions, R&D restructuring, outsourcing and active lifecycle management) adopted by the pharmaceutical industry to tackle these challenges and improve the R&D efficiency. The report substantiates the analysis with various case studies to study the effect of measure post-implementation. The report also provides an analytical insight into the potential solutions that have tremendous potential to improve the future pharmaceutical and biotech R&D productivity.
The pharmaceutical industry has witnessed a significant decline in R&D productivity over the past few years, which has become a matter of concern among the key stakeholders in the industry, particularly the pharmaceutical companies. While the R&D expenditure of the industry has steadily increased, the output has been declining. The increase in the number of late-stage development failures is costing the pharmaceutical industry dearly. In addition, the stringent regulatory mechanisms on the pricing and reimbursement of approved drugs have added to the pressure. Pharmaceutical companies have tried many ways to improve the R&D efficiency which include the acquisitions of small biotechnology and pharmaceutical companies, R&D restructuring, outsourcing and better lifecycle management of their existing drugs in the market. However, there has been limited success achieved to date.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.
Scope
The report analyses the key measures adopted to improve the R&D efficiency in the pharmaceutical and biotech industry along with the major challenges that have led to a decrease in the R&D productivity over the last decade. The scope of the report includes:
• Major challenges in the current pharmaceutical R&D landscape.
• Key solutions adopted by the pharmaceutical industry to improve the R&D productivity which include strategic mergers and acquisitions, R&D restructuring, outsourcing and active lifecycle management.
• More than 25 examples and case studies explaining each solution and its impact on the R&D productivity in a short and long term.
• Qualitative analysis of the major potential solutions that can improve the R&D productivity in the future.
Reasons to buy
The report will enhance your decision making. It will allow you to:
• Identify the key R&D challenges in the industry and its impact on your company's R&D productivity.
• Understand the three different focus areas of improving R&D efficiency and select the one best suited to the company’s long term business strategy.
• Develop more efficient and effective solutions by identifying the implementation issues from the case studies and examples covered for each solution.
• Ensure sustainable R&D growth by identifying long term potential solutions to improve R&D efficiency.
• Create an integrated and agile R&D organization through the understanding of key technologies and other external partners in improving the R&D efficiency in future.
• Optimize R&D efforts by identifying the key areas with maximum revenue potential in future.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 GBI Research Report Guidance
3 Current Challenges in the Pharmaceutical R&D - Declining ROI and Stringent Pricing and Reimbursements are Major Impediments
3.1 Declining Return on Investment on R&D
3.1.1 Increasing R&D Costs against Declining NME/BLA (New Molecular Entities/Biologic License Application) Approvals in the Last 15 Years (1995-2009)
3.1.2 R&D Costs Increase against Revenue Growth for the Top 10 Pharma Companies
3.2 Adverse Pricing and Reimbursement Regime for New Drugs
3.2.1 Pressure to Curb Healthcare Costs Driving the Increased Adoption of Stringent Pricing Mechanisms
3.2.2 Economic Evaluations Gaining Importance as a Key Parameter for Reimbursement Decisions
3.3 Generic Competition and Increasing Number of Patent Challenges
4 Major Steps Taken by Pharmaceutical Companies to Improve R&D Efficiency - Significant but Ineffective
4.1 R&D Components to Concentrate on Increasing Efficiency
4.1.1 Decrease Cost - Short Term Solution
4.1.2 Improve Returns from the Same Level of Output - Limited Success Potential Solution
4.1.3 Increased Output (Number of Drugs) - Long Term Solution
4.1.4 Combining Multiple Strategies for Optimum Results
4.2 Strategic Consolidations
4.2.1 Top Five Major Industry Consolidations in the Last Decade
4.3 Restructuring the R&D
4.3.1 GlaxoSmithKline - Realigning Focus to Vaccines, Consumer Healthcare and Emerging Markets
4.3.2 Pfizer - Redefining the Research Focus and Outsourcing the Rest
4.3.3 AstraZeneca - Consolidating R&D Facilities with Narrowed Therapeutic Focus
4.3.4 Sanofi-Aventis - Combining Workforce Consolidation with Externalization to Safeguard Future Revenues
4.4 Outsourcing R&D to Low Cost Countries - Particularly the Early Stage Research
4.4.1 Role of CROs in Providing Cost Efficiencies
4.4.2 Drug Discovery Research Outsourcing -Focus on India and China
4.5 Better Lifecycle Management of Existing Drugs
4.5.1 Indication Expansion
4.5.2 Extended/Controlled Release Versions
4.5.3 New Formulations
4.6 Critical Path Initiative
5 Potential Solutions - Information Technology and External Collaborations to Play a Key Role in Reviving R&D Prospects
5.1 Solving the Root of the Problem - Improving Discovery Research
5.1.1 Failure Rates in Phase I/II/III
5.1.2 Improving Drug Discovery Process
5.1.3 Improving Clinical Trials Design
5.2 Information Technology - Key Success Factor in Optimizing R&D Costs
5.2.1 Effective Data Management Is Critical For R&D Productivity
5.2.2 Technology Support Inevitable For Personalized Medicine: The Future Class of Medicines
5.2.3 Paperless Clinical Trials - A Billion Dollar Saving Potential
5.3 Network R&D - Involving External Partners to Complement Internal R&D Capabilities
5.4 R&D Hive-off
5.4.1 AstraZeneca’s Alberio
5.4.2 Sanofi-Aventis’ Novexel
5.5 Establishing Focus on Niche Markets
6 Conclusion
7 Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Primary Research
7.3.4 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 GBI Research Report Guidance
3 Current Challenges in the Pharmaceutical R&D - Declining ROI and Stringent Pricing and Reimbursements are Major Impediments
3.1 Declining Return on Investment on R&D
3.1.1 Increasing R&D Costs against Declining NME/BLA (New Molecular Entities/Biologic License Application) Approvals in the Last 15 Years (1995-2009)
3.1.2 R&D Costs Increase against Revenue Growth for the Top 10 Pharma Companies
3.2 Adverse Pricing and Reimbursement Regime for New Drugs
3.2.1 Pressure to Curb Healthcare Costs Driving the Increased Adoption of Stringent Pricing Mechanisms
3.2.2 Economic Evaluations Gaining Importance as a Key Parameter for Reimbursement Decisions
3.3 Generic Competition and Increasing Number of Patent Challenges
4 Major Steps Taken by Pharmaceutical Companies to Improve R&D Efficiency - Significant but Ineffective
4.1 R&D Components to Concentrate on Increasing Efficiency
4.1.1 Decrease Cost - Short Term Solution
4.1.2 Improve Returns from the Same Level of Output - Limited Success Potential Solution
4.1.3 Increased Output (Number of Drugs) - Long Term Solution
4.1.4 Combining Multiple Strategies for Optimum Results
4.2 Strategic Consolidations
4.2.1 Top Five Major Industry Consolidations in the Last Decade
4.3 Restructuring the R&D
4.3.1 GlaxoSmithKline - Realigning Focus to Vaccines, Consumer Healthcare and Emerging Markets
4.3.2 Pfizer - Redefining the Research Focus and Outsourcing the Rest
4.3.3 AstraZeneca - Consolidating R&D Facilities with Narrowed Therapeutic Focus
4.3.4 Sanofi-Aventis - Combining Workforce Consolidation with Externalization to Safeguard Future Revenues
4.4 Outsourcing R&D to Low Cost Countries - Particularly the Early Stage Research
4.4.1 Role of CROs in Providing Cost Efficiencies
4.4.2 Drug Discovery Research Outsourcing -Focus on India and China
4.5 Better Lifecycle Management of Existing Drugs
4.5.1 Indication Expansion
4.5.2 Extended/Controlled Release Versions
4.5.3 New Formulations
4.6 Critical Path Initiative
5 Potential Solutions - Information Technology and External Collaborations to Play a Key Role in Reviving R&D Prospects
5.1 Solving the Root of the Problem - Improving Discovery Research
5.1.1 Failure Rates in Phase I/II/III
5.1.2 Improving Drug Discovery Process
5.1.3 Improving Clinical Trials Design
5.2 Information Technology - Key Success Factor in Optimizing R&D Costs
5.2.1 Effective Data Management Is Critical For R&D Productivity
5.2.2 Technology Support Inevitable For Personalized Medicine: The Future Class of Medicines
5.2.3 Paperless Clinical Trials - A Billion Dollar Saving Potential
5.3 Network R&D - Involving External Partners to Complement Internal R&D Capabilities
5.4 R&D Hive-off
5.4.1 AstraZeneca’s Alberio
5.4.2 Sanofi-Aventis’ Novexel
5.5 Establishing Focus on Niche Markets
6 Conclusion
7 Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Primary Research
7.3.4 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources
Browse all Healthcare reports
http://www.reportsandreports.com/market-research/healthcare/
Browse GBI Research Reports at
http://www.reportsandreports.com/Publishers/gbi-research/
Related Reports
Pancreatic Cancer - Drug Pipeline Analysis and Market Forecasts to 2016
http://www.reportsandreports.com/market-reports/pancreatic-cancer-drug-pipeline-analysis-and-market-forecasts-t/
Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016
http://www.reportsandreports.com/market-reports/neutropenia-drug-pipeline-analysis-and-market-forecasts-to-2016/
Growth Hormone Deficiency (GHD) - Pipeline Analysis and Market Forecasts to 2016
http://www.reportsandreports.com/market-reports/growth-hormone-deficiency-ghd-pipeline-analysis-and-market-fo/
About ReportsandReports
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://www.reportsandreports.com/
Visit our Blog: http://reportsnreports.wordpress.com/
Pharmaceutical Research and Development (R&D) - Increasing Efficiency Through Information Technology and Externalization Report Now Available on ReportsandReports
This pharmaceutical and healthcare report provides comprehensive insight into the major challenges in the current pharmaceutical R&D landscape. It analyzes key measures and practices (mergers and acquisitions, R&D restructuring, outsourcing and active lifecycle management)